文献速递痛风与晶体性关节病

二甲双胍与钠-葡萄糖协同转运蛋白-2抑制剂使用者的痛风发病率:一项回顾性队列研究

Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该回顾性队列研究基于JMDC理赔数据库2014至2022年数据,比较糖尿病患者起始二甲双胍与SGLT-2i者的痛风发病率。经倾向评分IPTW后,二甲双胍与SGLT-2i相比痛风风险无显著差异(HR 0.90,95%CI 0.63-1.28),但二甲双胍组血清尿酸水平降幅较小(差异0.48 mg/dl)。

要点

  • 二甲双胍组痛风发病率为2.40/1000人年,SGLT-2i组为3.15/1000人年。
  • IPTW后二甲双胍与痛风风险降低无显著关联(HR 0.90,95%CI 0.63-1.28)。
  • 二甲双胍组1年后血清尿酸变化较SGLT-2i组高0.48 mg/dl(95%CI 0.43-0.52)。

核心结论

  • 在糖尿病患者中,二甲双胍与SGLT-2i的痛风风险可能相当,二甲双胍对血清尿酸水平的降低幅度小于SGLT-2i。

研究设计与样本

  • 回顾性新使用者比较效果研究,纳入JMDC理赔数据库2014至2022年有健康体检和行政理赔数据的成人糖尿病患者。
  • 比较起始二甲双胍者与起始SGLT-2i者,主要结局为新发痛风诊断。
  • 经倾向评分逆概率治疗加权(IPTW)后,采用Cox比例风险模型估计风险比(HR)及95%CI,线性混合模型评估两组与血清尿酸水平变化的关联。
  • 共纳入21561例糖尿病患者,其中男性17636例,平均年龄53岁;二甲双胍组13535例,SGLT-2i组8026例。

主要发现

  • 二甲双胍组痛风发病率为2.40/1000人年,SGLT-2i组为3.15/1000人年。
  • IPTW后,二甲双胍与SGLT-2i相比痛风风险无显著差异(HR 0.90,95%CI 0.63-1.28;率差-0.28,95%CI -1.24至0.68/1000人年)。
  • 索引日期后1年血清尿酸水平变化,二甲双胍组相对于SGLT-2i组的平均差异为0.48 mg/dl(95%CI 0.43-0.52)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the incidence of gout in individuals with diabetes receiving metformin vs sodium-glucose co-transporter-2 inhibitors (SGLT-2is). METHODS: This new-user comparative effectiveness study included adults from the JMDC claims database with health check-up and administrative claims data from 2014 to 2022. Individuals initiated on metformin were compared with those initiated on SGLT-2is. The primary outcome was the incidence of new gout diagnoses. After propensity-score inverse probability treatment weighting (IPTW), Cox proportional hazards models were fitted to estimate the hazard ratios (HRs) and 95% CIs. A linear mixed model was employed to assess the association between the two groups and changes in serum uric acid levels. RESULTS: A total of 21 561 individuals with diabetes were identified, including 17 636 males with a mean age of 53 years. The metformin and SGLT-2i groups included 13 535 and 8026 individuals, respectively. In the metformin and SGLT-2i groups, the gout incidence rates were 2.40 and 3.15 events per 1000 person-years, respectively. After IPTW, metformin was not associated with a decreased risk of gout compared with SGLT-2i (HR 0.90, 95% CI 0.63-1.28; rate difference -0.28, 95% CI -1.24 to 0.68 events per 1000 person-years). The mean difference in serum uric acid level change 1 year after the index date was 0.48 mg/dl (95% CI 0.43-0.52) for the metformin group relative to the SGLT-2i group. CONCLUSION: Gout risk may be comparable between metformin and SGLT-2is in individuals with diabetes, with metformin showing a lesser reduction in serum uric acid levels than SGLT-2is.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hatano M, Okada A, Sasabuchi Y, et al. Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study. Rheumatology (Oxford). 2025. PMID: 40127201. doi:10.1093/rheumatology/keaf136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。